Screener
Vertex Pharmaceuticals VRTX Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.
The source filing: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000875320-26-000173
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $5,492.9 | $5,084.8 |
| Marketable securities | 1,753.8 | 1,523.3 |
| Accounts receivable, net | 1,996.1 | 2,052.8 |
| Inventories | 1,766.7 | 1,686.8 |
| Prepaid expenses and other current assets | 720.8 | 853.3 |
| Total current assets | 11,730.3 | 11,201.0 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Vertex Pharmaceuticals's short-term investments?
- Vertex Pharmaceuticals (VRTX) reported short-term investments of $1.75B in Q1 2026.
- How has Vertex Pharmaceuticals's short-term investments changed year-over-year?
- Vertex Pharmaceuticals's short-term investments increased by 14.9% year-over-year, from $1.53B to $1.75B.
- What is the long-term trend for Vertex Pharmaceuticals's short-term investments?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's short-term investments has grown at a 17.8% compound annual growth rate (CAGR), from $670.7M to $1.52B.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Vertex Pharmaceuticals's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude